Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 3;13(1):65.
doi: 10.1038/s41408-023-00834-6.

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

Francesca Palandri  1 , Elena M Elli  2 , Giuseppe Auteri  3   4 , Massimiliano Bonifacio  5 , Giulia Benevolo  6 , Florian H Heidel  7 , Simona Paglia  3 , Malgorzata M Trawinska  8 , Costanza Bosi  9 , Elena Rossi  10   11 , Mario Tiribelli  12 , Alessia Tieghi  13 , Alessandra Iurlo  14 , Nicola Polverelli  15 , Giovanni Caocci  16 , Gianni Binotto  17 , Francesco Cavazzini  18 , Eloise Beggiato  6 , Daniela Cilloni  19 , Caterina Tatarelli  20 , Francesco Mendicino  21 , Maurizio Miglino  22   23 , Monica Bocchia  24 , Monica Crugnola  25 , Camilla Mazzoni  3   4 , Andrea D Romagnoli  3   4 , Giovanni Rindone  2 , Sara Ceglie  10 , Alessandra D'Addio  26 , Eleonora Santoni  5 , Daniele Cattaneo  14 , Daniela Bartoletti  3 , Roberto M Lemoli  22   23 , Mauro Krampera  5 , Antonio Cuneo  18 , Gianpietro C Semenzato  17 , Roberto Latagliata  27 , Elisabetta Abruzzese  8 , Nicola Vianelli  3 , Michele Cavo  3   4 , Alessandro Andriani  28 , Valerio De Stefano  10   11 , Giuseppe A Palumbo  29 , Massimo Breccia  30
Affiliations

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

Francesca Palandri et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

F.P. consultancy and honoraria from Novartis, Celgene, AOP, Sierra Oncology and CTI; G.Be. honoraria from Novartis, Janssen, Amgen, Takeda, BMS; A.Iu., M.Br. and M.Bo. honoraria from Novartis, BMS, Pfizer, Incyte; M.Cr honoraria from Novartis, Amgen; G.S. honoraria from Abbvie, Roche, Takeda; G.Bi. honoraria from Novartis, Incyte, BMS-Celgene, Pfizer; R.M.L. honoraria from Jazz, Pfizer, AbbVie, BMS, Sanofi, StemLine. F.H.H. consultancy for Novartis, CTI and Celgene and research funding from Novartis; M. Ca acted as consultant and received honoraria from Jannsen, BMS Celgene, SanoFI, GlaxoSmithKline, Takeda, Amgen, Oncopeptides, AbbVie, Karyopharm, and Adaptive. E. A. honoraria from Novartis, BMS, Pfizer, and Incyte. N.V. consultancy and honoraria from Novartis, Amgen, Sobi, Grifols e Sanofi. V.D.S. consultant honoraria and speaker fees from AbbVie, Alexion, Amgen, AOP Health, Argenx, Bristol Myers Squibb, Grifols, GlaxoSmithKline, Leo Pharma, Novartis, Novo Nordisk, Sanofi, SOBI, Takeda. D. C. honoraria from Novartis, BMS, Incyte and Pfizer. M.B. honoraria from Novartis, Incyte, Astrazeneca, Jannsen. G.A.P. honoraria from Abbvie, AOP, AstraZeneca, BMS Celgene, Novartis, Incyte, Jannsen, Takeda; M. T. consultancy and honoraria from Novartis. M. M. T. consultancy and honoraria from Novartis. F.C. honoraria from Novartis, Incyte, and Pfizer, R.L. honoraria from Novartis, Celgene, BMS, Janssen; E.R., A.D., E.S., A.A, S.C., M.K, N.P., G.A., S.P., D.B., A.D.R., C.M., G.C, G.R., E.M.E., M.F., A.C., E.B., C.T, C.B., D.C., M.M., A.T. have no conflict of interest to disclose.

Figures

Fig. 1
Fig. 1. Risk factors.
Risk factors associated with hospitalization (a) and survival after Covid19 (b). Overall, the percentage of patients aged ≥ 70 or with NLR ≥ 5.5 was comparable across the three Covid19 waves. Risk factors for hospitalization and mortality were calculated by Cox proportional hazard model.
See this image and copyright information in PMC

References

    1. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737–45. doi: 10.1016/S2352-3026(20)30251-9. - DOI - PMC - PubMed
    1. Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia [Internet] 2021;35:485–93. doi: 10.1038/s41375-020-01107-y. - DOI - PMC - PubMed
    1. Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol [Internet] 2021;96:145–62. doi: 10.1002/ajh.26050. - DOI - PubMed
    1. Elli EM, Baratè C, Mendicino F, Palandri F, Palumbo GA. Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Front Oncol [Internet] 2019;9:1186.. doi: 10.3389/fonc.2019.01186. - DOI - PMC - PubMed
    1. Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia [Internet] 2021;35:485–93. doi: 10.1038/s41375-020-01107-y. - DOI - PMC - PubMed

Publication types